Finerenone for Chronic Kidney Disease
(FIND-CKD Trial)

Recruiting in Palo Alto (17 mi)

+539 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: Bayer

Pivotal Trial (Near Approval)

Prior Safety Data

Approved in 2 Jurisdictions

Trial Summary

What is the purpose of this trial?This trial is testing finerenone, a daily pill, to help people with non-diabetic chronic kidney disease. Finerenone works by blocking a hormone called aldosterone that can cause damage and swelling in the heart and kidneys. The goal is to see if finerenone can slow down the worsening of kidney disease. Finerenone has shown promise in reducing kidney disease progression in patients with chronic kidney disease and type 2 diabetes.

Eligibility Criteria

Adults with non-diabetic chronic kidney disease (CKD) can join this trial. They must have a certain level of protein in their urine and a specific range of kidney function. Participants should be on stable doses of ACE inhibitors or ARBs for at least 4 weeks before the trial starts, without severe heart failure or diabetes, and not require immunosuppressive therapy for other kidney diseases.

Inclusion Criteria

My kidney tests show specific levels of protein in my urine and a certain rate of filtration.

I have been diagnosed with chronic kidney disease.

I have been on a stable dose of ACEI or ARB medication for at least 4 weeks.

+2 more

Exclusion Criteria

I have a genetic form of polycystic kidney disease.

I have a kidney condition treated with immune-suppressing drugs in the last 6 months.

I have been diagnosed with Type 1 or Type 2 Diabetes, or my HbA1c level is 6.5% or higher.

+1 more

Participant Groups

The trial is testing if finerenone, a tablet taken once daily that blocks the hormone aldosterone, can slow down CKD progression compared to a placebo. The study will last up to about 50 months and involves regular health checks plus blood and urine tests while continuing current CKD medications.

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Finerenone (BAY94-8862)Experimental Treatment1 Intervention

Participants will receive finerenone.

Group II: PlaceboPlacebo Group1 Intervention

Participants will receive placebo.

Finerenone is already approved in United States, European Union for the following indications:

🇺🇸 Approved in United States as Kerendia for: